Considering the levels of TILs pre‐ versus posttreatment (normalised against tumour cell population), we observed a significant increase in both the CD4+ and CD8+ T‐cell/tumour cell ratios, in the PI3K/mTORi‐ and PI3K/mTORi+PD‐1i‐treated conditions but not in the PD‐1i‐ or vehicle‐treated tumours (Figure 3C). This evidence concerns the gene CD4 and neoplasm.